277 related articles for article (PubMed ID: 28860413)
1. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
2. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
5. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
6. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
Pandey K; An HJ; Kim SK; Lee SA; Kim S; Lim SM; Kim GM; Sohn J; Moon YW
Int J Cancer; 2019 Sep; 145(5):1179-1188. PubMed ID: 30478914
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Spring LM; Wander SA; Andre F; Moy B; Turner NC; Bardia A
Lancet; 2020 Mar; 395(10226):817-827. PubMed ID: 32145796
[TBL] [Abstract][Full Text] [Related]
13. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
14. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
Sarosiek T
Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
[TBL] [Abstract][Full Text] [Related]
18. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
